RAFFA WEALTH MANAGEMENT, LLC’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$907 Buy
4
+1
+33% +$178 ﹤0.01% 1047
2026
Q1
$518 Hold
3
﹤0.01% 1064
2025
Q4
$598 Hold
3
﹤0.01% 1044
2025
Q3
$469 Sell
3
-55
-95% -$8.73K ﹤0.01% 1083
2025
Q2
$8.8K Buy
58
+55
+1,833% +$7.33K ﹤0.01% 403
2025
Q1
$452 Hold
3
﹤0.01% 978
2024
Q4
$554 Hold
3
﹤0.01% 987
2024
Q3
$591 Hold
3
﹤0.01% 963
2024
Q2
$620 Hold
3
﹤0.01% 1013
2024
Q1
$813 Hold
3
﹤0.01% 940
2023
Q4
$709 Hold
3
﹤0.01% 910
2023
Q3
$588 Hold
3
﹤0.01% 913
2023
Q2
$631 Hold
3
﹤0.01% 918
2023
Q1
$605 Hold
3
﹤0.01% 922
2022
Q4
$654 Hold
3
﹤0.01% 894
2022
Q3
$590 Hold
3
﹤0.01% 982
2022
Q2
$642 Hold
3
﹤0.01% 953
2022
Q1
$852 Hold
3
﹤0.01% 923
2021
Q4
$1.13K Hold
3
﹤0.01% 825
2021
Q3
$1.24K Hold
3
﹤0.01% 755
2021
Q2
$1.11K Hold
3
﹤0.01% 793
2021
Q1
$869 Buy
+3
New +$834 ﹤0.01% 879

Other funds holding CRL

RAFFA WEALTH MANAGEMENT, LLC's CRL Position: Q2 2026 in Review

RAFFA WEALTH MANAGEMENT, LLC increased its Charles River Laboratories (CRL) stake by 33% in Q2 2026, buying an estimated $178 and bringing the position to 4 shares worth $907. The position accounts for ﹤0.01% of the portfolio, ranked #1047.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in CRL in Q1 2021 and has held it in 22 quarters since. The position peaked at $8.8K in Q2 2025. 137 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • RAFFA WEALTH MANAGEMENT, LLC held 4 shares of Charles River Laboratories worth $907 as of Q2 2026.
  • RAFFA WEALTH MANAGEMENT, LLC bought 1 Charles River Laboratories share in Q2 2026, an estimated $178.
  • Charles River Laboratories made up ﹤0.01% of RAFFA WEALTH MANAGEMENT, LLC's portfolio in Q2 2026, its #1047 holding.
  • RAFFA WEALTH MANAGEMENT, LLC first reported a position in Charles River Laboratories in Q1 2021 and has held it in 22 quarters since.
  • RAFFA WEALTH MANAGEMENT, LLC's Charles River Laboratories position peaked at $8.8K in Q2 2025.
  • 137 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2026, filed 27 Jul 2026.